169 related articles for article (PubMed ID: 17688233)
1. Has economics overshadowed our clinical approaches to EPO?
Sullivan JD
Nephrol News Issues; 2007 Jul; 21(8):56, 58-9, 68. PubMed ID: 17688233
[No Abstract] [Full Text] [Related]
2. A lesson from the EPO mess: stop the cost shifting.
Amerling R
Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232
[No Abstract] [Full Text] [Related]
3. Anemia: dialysis patients experiences.
Schatell D; Witten B
Nephrol News Issues; 2004 Nov; 18(12):49-54. PubMed ID: 15595502
[No Abstract] [Full Text] [Related]
4. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
5. NRAA responds to proposed $1 cut in EPO reimbursement.
Nephrol News Issues; 1998 Apr; 12(4):12-3. PubMed ID: 9601363
[No Abstract] [Full Text] [Related]
6. Finding the magic formula for ESA use.
Neumann ME
Nephrol News Issues; 2010 May; 24(6):8. PubMed ID: 20509399
[No Abstract] [Full Text] [Related]
7. ESA payment changes: chasing a moving target.
Sargent JA
Nephrol News Issues; 2008 Jan; 22(1):36-7. PubMed ID: 18271437
[No Abstract] [Full Text] [Related]
8. Current and future challenges in anaemia management.
Levin A; Locatelli F; Muirhead N; Ritz E
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi1-2. PubMed ID: 15958819
[No Abstract] [Full Text] [Related]
9. Is it time to reconsider subcutaneous administration of epoetin?
Patel TV; Robinson K; Singh AK
Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
[TBL] [Abstract][Full Text] [Related]
10. Capturing Epogen overfill.
Wiseman K
Nephrol Nurs J; 2000 Aug; 27(4):407, 415. PubMed ID: 11276633
[No Abstract] [Full Text] [Related]
11. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
Hayslip D
Nephrol Nurs J; 2008; 35(2):163-7. PubMed ID: 18472685
[TBL] [Abstract][Full Text] [Related]
12. Anemia and response to epoetin alfa: the cause of anemia matters!
Dharmarajan TS
J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
[No Abstract] [Full Text] [Related]
13. Anemia of chronic disease, older adults, and medicare.
Hardin SR
J Gerontol Nurs; 2010 Oct; 36(10):3-4. PubMed ID: 20954598
[No Abstract] [Full Text] [Related]
14. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
Messana T
Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
[TBL] [Abstract][Full Text] [Related]
15. Relative mortality and epoetin alpha dose among hemodialysis patients.
Coyne DW
Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
[No Abstract] [Full Text] [Related]
16. Relative mortality and epoetin alpha dose in hemodialysis patients.
Cotter DJ; Thamer M; Zhang Y
Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
[No Abstract] [Full Text] [Related]
17. Anaemia of CKD--the CHOIR study revisited.
Singh AK; Szczech L; Tang KL; Barnhart H; Sapp S; Wolfson M; Reddan D
Nephrol Dial Transplant; 2007 Jul; 22(7):1806-10. PubMed ID: 17420166
[No Abstract] [Full Text] [Related]
18. Erythropoietin claims monitoring policy: implications for clinical practice.
Messana T
Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
[TBL] [Abstract][Full Text] [Related]
19. Epoetin bubble: a severe German case Honi soit qui mal y pense.
Wizemann V
Nephrol Dial Transplant; 2011 May; 26(5):1750-2; author reply 1752. PubMed ID: 21378149
[No Abstract] [Full Text] [Related]
20. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
